Granulocyte colony stimulating factor treatment for neonatal neutropenia.
In a pilot study recombinant human granulocyte colony-stimulating factor (rhG-CSF) was administered to 12 neutropenic preterm infants to determine if neonatal neutropenia is secondary to decreased endogenous G-CSF production. Respiratory variables were monitored because of the possible link between inflammatory cells and hyaline membrane disease. All infants showed increased neutrophil counts. The only possible side effect observed was an exacerbation of thrombocytopenia.
Russell
A R
AR
Department of Child Health, St George's Hospital Medical School, London.
Davies
E G
EG
Ball
S E
SE
Gordon-Smith
E
E
D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D007958:Leukocyte Count; D009503:Neutropenia / Q000097:blood / Q000628:therapy*; D010865:Pilot Projects; D013921:Thrombocytopenia / Q000209:etiology
D016179:Granulocyte Colony-Stimulating Factor